急诊科酒精戒断综合征:苯巴比妥辅助治疗与单用苯二氮䓬类方案的比较
该回顾性队列研究在美国两家学术急诊科开展,纳入209例急诊酒精戒断综合征成人患者,按是否在急诊使用苯巴比妥分为苯巴比妥组(97例,可联用苯二氮䓬类)与非苯巴比妥组(112例)。主要终点ICU入住率在两组间相似(苯巴比妥组14% vs 非苯巴比妥组11%,p=0.529)。离院时CIWA-Ar评分中位数两组均为7分(苯巴比妥组IQR 4-12 vs 非苯巴比妥组IQR 4-14,p=0.752),并发症复合终点发生率也相似(9% vs 11%)。结论认为急诊加用苯巴比妥并未减少ICU入住、症状严重程度或并发症。
要点
- 在209例急诊酒精戒断综合征成人中,苯巴比妥组ICU入住率14%(14/97) vs 非苯巴比妥组11%(12/112),p=0.529,无显著差异。
- 离院时CIWA-Ar评分中位数苯巴比妥组7分(IQR 4-12) vs 非苯巴比妥组7分(IQR 4-14),p=0.752,无显著差异。
- 并发症复合终点(死亡、插管、低血压或升压药使用、癫痫发作、医院获得性肺炎)苯巴比妥组9%(9/97) vs 非苯巴比妥组11%(10/112),两组相似。
- 该研究为回顾性队列,苯巴比妥组可联用苯二氮䓬类,非苯巴比妥组为不用苯巴比妥者,分组非随机。
适用人群与场景
- 美国两家学术急诊科就诊、诊断为酒精戒断综合征的成人患者,共209例(苯巴比妥组97例,非苯巴比妥组112例)。
研究设计与关键结果
- 研究类型:回顾性队列研究,美国两家学术急诊科,样本量209例(苯巴比妥组97例,非苯巴比妥组112例),平均年龄49(标准差12)岁,男性85%(n=178)。
- 主要终点:需ICU入住比例苯巴比妥组14%(n=14) vs 非苯巴比妥组11%(n=12),p=0.529,无显著差异。
- 次要终点:离院时CIWA-Ar评分中位数苯巴比妥组7分(IQR 4-12) vs 非苯巴比妥组7分(IQR 4-14),p=0.752,无显著差异。
- 并发症复合终点(死亡、需插管、低血压或使用升压药、癫痫发作、医院获得性肺炎)苯巴比妥组9%(n=9) vs 非苯巴比妥组11%(n=10),两组相似。
证据类型、等级与局限
- 证据类型:回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 原文结论:急诊加用苯巴比妥治疗酒精戒断综合征未减少ICU入住、症状严重程度或并发症。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: To compare a phenobarbital-adjunct versus benzodiazepine-only approach for the management of alcohol withdrawal syndrome in the emergency department (ED) with regard to the need for intensive care unit (ICU) admission, severity of symptoms on ED discharge, and complications.
METHODS: This was a retrospective cohort study conducted in two academic EDs in the United States. Adult patients seen in the ED with a diagnosis of alcohol withdrawal syndrome were included. Patients were categorized into two groups based on whether phenobarbital was administered in the ED: 1) phenobarbital group (with or without benzodiazepines) or 2) non-phenobarbital group. The primary outcome measure was the need for ICU admission. Secondary outcomes included Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scores at ED discharge, and complications. Complications were a composite of death, need for intubation, hypotension or vasopressor use, seizures, and hospital acquired pneumonia.
RESULTS: The study cohort included 209 patients (phenobarbital = 97, non-phenobarbital = 112). The mean (standard deviation) age was 49 (12) years and 85% (n = 178) were male. A similar proportion of patients in the phenobarbital (14%, n = 14) and non-phenobarbital (11%, n = 12) groups required ICU admission (p = 0.529). The median CIWA-Ar score on ED discharge was 7 (IQR 4-12) points in the phenobarbital group and 7 (IQR 4-14) points in the non-phenobarbital group (p = 0.752). The occurrence of complications was also similar in the phenobarbital (9%, n = 9) and non-phenobarbital groups (11%, n = 10).
CONCLUSION: Adjunctive phenobarbital use in the ED for alcohol withdrawal syndrome did not result in decreased ICU admission, severity of symptoms, or complications.
参考来源
- Sullivan SM, Dewey BN, Jarrell DH, et al. Comparison of phenobarbital-adjunct versus benzodiazepine-only approach for alcohol withdrawal syndrome in the ED. Am J Emerg Med. 2018. PMID: 30414743. doi:10.1016/j.ajem.2018.10.007
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。